By Fineline Cube 
Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.
New Restrictions
In the commercial setting, non-ambulatory patients will no longer receive Elevidys treatment. In clinical trial settings, enrollment and dosing for non-ambulatory patients will be suspended immediately until additional risk mitigation measures, such as immunomodulatory therapy, are implemented in the study protocols.
Drug Background
Elevidys is a recombinant gene therapy that uses an AAV viral vector to deliver a transgene encoding micro-dystrophin. Administered via a single intravenous infusion, it enables patients’ muscles to produce a recombinant protein with partial dystrophin functionality. It is effective for patients with any type of DMD-causing genetic variant.
Regulatory Context
In March 2025, the European Medicines Agency (EMA) paused Elevidys’ Phase III clinical trial in Europe following the death of a patient who did not meet the study criteria. The patient developed acute liver failure (ALF) after receiving Elevidys. The decision to adjust dosing was prompted by this incident, as acute liver failure is a known risk of Elevidys and other AAV-mediated gene therapies.
Benefit-Risk Reassessment
The new dosing restrictions reflect a reassessment of the benefit-risk ratio for non-ambulatory DMD patients, which is now deemed unfavorable. However, the restrictions do not affect treatment for ambulatory DMD patients of any age, where the benefit-risk ratio remains positive.-Fineline Info & Tech